Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 6/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.49 |
| ▸ | USP2 | O75604 | 4/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19083685 | 0.85 | CYP2D6 (0.52) | CYP2D6CYP3A4USP2CYP2C19CYP1A2 | |
| SCHEMBL19084132 | 0.84 | CYP2D6 (0.51) | CYP2D6CYP3A4USP2CYP2C19CYP1A2 | |
| SCHEMBL23118445 | 0.83 | CYP2D6 (0.50) | CYP2D6CYP3A4USP2CYP2C19CYP1A2 | |
| SCHEMBL21075596 | 0.78 | KCNH2 (0.42) | CYP2D6CYP3A4USP2CYP2C19CYP1A2 | |
| SCHEMBL19075617 | 0.78 | SCN9A (0.45) | CYP2D6CYP3A4USP2CYP2C19CYP1A2 | |
| SCHEMBL19083729 | 0.76 | OPRL1 (0.46) | OPRL1ALDH1A1KCNH2OPRM1KDM4E | |
| SCHEMBL19075631 | 0.76 | FAAH (0.45) | CYP2D6OPRL1ALDH1A1FAAHKCNH2 | |
| SCHEMBL19083894 | 0.76 | ACHE (0.50) | CYP2D6CYP3A4USP2CYP2C19CYP1A2 | |
| SCHEMBL19075557 | 0.75 | ALDH1A1 (0.44) | OPRL1ALDH1A1KDM4E | |
| SCHEMBL19075613 | 0.74 | MGAT2 (0.45) | CYP2D6CYP3A4USP2CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-01-31 | — | — | US | disclosed |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | CYP2D6 189/4885CYP3A4 594/4885USP2 4357/4885 |
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | CYP2D6 189/4885CYP3A4 594/4885USP2 4357/4885 |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | CYP2D6 189/4885CYP3A4 594/4885USP2 4357/4885 |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | CYP2D6 189/4885CYP3A4 594/4885USP2 4357/4885 |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | CYP2D6 189/4885CYP3A4 594/4885USP2 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.